HBM Holdings (HKG:2142) repurchased HK$10 million worth of shares on Feb. 7, the most for biotech firms on the Hong Kong Stock Exchange, according to a Monday filing with the bourse.
The buyback is a part of a HK$40 million buyback plan to enhance shareholder value.
CEO and chairman of the board Jingsong Wang increased his stake in the company and did not rule out further stake increase.
With cash reserves of HK$1.43 billion, the company is strengthening its business by partnering with companies like Windward Bio and Kodiak Sciences. These collaborations aim to advance research and develop innovative treatments in key areas such as immunology and ophthalmology.
The company's shares were up by 15% in recent trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。